Pharmacological Reduction of Functional, Ischemic Mitral REgurgitation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 118 participants.

Also called NCT02687932

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 118 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02687932
Other papers using this trial's data
  • Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation Circulation, 2019-03-12 DOI, PubMed 30586756

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02687932. Randomized; quadruple masking; primary purpose treatment. Start 2016-03 (actual); primary completion 2018-01-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Pharmacological Reduction of Functional, Ischemic Mitral REgurgitation
Acronym
PRIME
Condition
Mitral Valve Insufficiency
Condition
Left Ventricular Dysfunction
Intervention (Drug)
LCZ696
Intervention (Drug)
Valsartan
Lead sponsor
Asan Medical Center (class: other)
Collaborator
Novartis (class: industry)

Record details

Record id
cardio:ct-nct02687932
Content hash
a9788c90ea8b19224d791129ba6a8af48330afca55d996048be8ecb1ff3418e3